Results 271 to 280 of about 2,450,308 (424)

Points-of-care Testing

Nursing Management (Springhouse), 1998
openaire   +3 more sources

ShcD adaptor protein drives invasion of triple negative breast cancer cells by aberrant activation of EGFR signaling

Molecular Oncology, EarlyView.
We identified adaptor protein ShcD as upregulated in triple‐negative breast cancer and found its expression to be correlated with reduced patient survival and increased invasion in cell models. Using a proteomic screen, we identified novel ShcD binding partners involved in EGFR signaling pathways.
Hayley R. Lau, Hayley S. Smith, Begüm Alural, Claire E. Martin, Laura A. New, Manali Tilak, Sara L. Banerjee, Hannah N. Robeson, Nicolas Bisson, Anne‐Claude Gingras, Jasmin Lalonde, Nina Jones   +11 more
wiley   +1 more source

Usefulness of Point-of-Care Testing for Respiratory Viruses in a Pediatric Emergency Department Setting. [PDF]

J Clin Med
Bellini T, Fueri E, Formigoni C, Mariani M, Villa G, Finetti M, Marin M, De Chiara E, Bratta A, Vanorio B, Casabona F, Pepino C, Castagnola E, Piccotti E, Moscatelli A.   +14 more
europepmc   +1 more source

Modelling the cost effectiveness of rapid point of care diagnostic tests for the control of HIV and other sexually transmitted infections among female sex workers [PDF]

, 2006
Peter Vickerman
openalex   +1 more source

Interplay of integrins and selectins in metastasis

Molecular Oncology, EarlyView.
Here we review the role of integrins and their interplay with selectins in metastasis. The efficacy of integrin‐targeted therapies may be reduced in tumors where metastasis relies heavily on selectins. In certain tumors, integrins and selectins exhibit a synergistic interaction during intraperitoneal dissemination.
Diana Maltseva, Ashot Nersisyan, Alexander Tonevitsky   +2 more
wiley   +1 more source

Effect of Point-of-care Influenza Testing on Management of Febrile Children [PDF]

, 2006
Srikant Iyer, Michael A. Gerber, Wendy J. Pomerantz, Joel E. Mortensen, Richard M. Ruddy   +4 more
openalex   +1 more source

A review on advances in methods for modification of paper supports for use in point-of-care testing

Microchimica Acta, 2019
Ruihua Tang, Li Na Liu, S. Zhang, Xiaocong He, Xiujun Li, Feng Xu, Y. Ni, Fei Li   +7 more
semanticscholar   +1 more source

Inhibitor of DNA binding‐1 is a key regulator of cancer cell vasculogenic mimicry

Molecular Oncology, EarlyView.
Elevated expression of transcriptional regulator inhibitor of DNA binding 1 (ID1) promoted cancer cell‐mediated vasculogenic mimicry (VM) through regulation of pro‐angiogenic and pro‐cancerous genes (e.g. VE‐cadherin (CDH5), TIE2, MMP9, DKK1). Higher ID1 expression also increased metastases to the lung and the liver.
Emma J. Thompson, Emma L. Dorward, Kristyn Jurrius, Nathalie Nataren, Markus Tondl, Kay K. Myo Min, Michaelia P. Cockshell, Anahita Fouladzadeh, John Toubia, Mark DeNichilo, Delphine Merino, Claudine S. Bonder   +11 more
wiley   +1 more source

One-Pot Assay Based on CRISPR/Cas13a Technology for HEV RNA Point-of-Care Testing. [PDF]

J Med Virol
Fan Z, Xu L, Cao Y, Liu T, Tian Y, Pan Z, Mo Y, Wang X, Zhu X, Gao Y, Zhang X, Pan CQ, Wang L, Ren F.   +13 more
europepmc   +1 more source

MET and NF2 alterations confer primary and early resistance to first‐line alectinib treatment in ALK‐positive non‐small‐cell lung cancer

Molecular Oncology, EarlyView.
Alectinib resistance in ALK+ NSCLC depends on treatment sequence and EML4‐ALK variants. Variant 1 exhibited off‐target resistance after first‐line treatment, while variant 3 and later lines favored on‐target mutations. Early resistance involved off‐target alterations, like MET and NF2, while on‐target mutations emerged with prolonged therapy.
Jie Hu, Ning Ding, Xiaobo Xu, Yedan Chen, Yong Zhang, Jingwen Liu, Jiebai Zhou, Hairong Bao, Donghui Zhang, Yijun Song, Yang Shao, Yuanlin Song   +11 more
wiley   +1 more source